

**DIVI'S LABORATORIES LIMITED**

UNAUDITED FINANCIAL RESULTS (STANDALONE)  
FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2012

(₹ in Lakhs)

Sl No.	Particulars	STANDALONE			
		Unaudited			Audited
		Quarter ended 30.06.2012	Quarter ended 31.03.2012	Quarter ended 30.06.2011	Year Ended 31.03.2012
	(1)	(2)	(3)	(4)	(5)
1	<b>Income from operations</b>				
	(a) Net Sales/Income from operations (Net of Excise Duty)	<b>46841</b>	70796	36128	183949
	(b) Other Operating Income	<b>110</b>	347	41	544
	<b>Total Income from operations (net)</b>	<b>46951</b>	71143	36169	184493
2	<u>Expenditure:</u>				
	a. Cost of materials consumed	<b>17138</b>	23664	17908	76868
	b. Purchases of stock-in-trade	<b>0</b>	10	0	10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(1174)</b>	7271	(3626)	(1066)
	d. Employee benefits expense	<b>4845</b>	4393	3296	14516
	e. Depreciation and amortization expense	<b>1748</b>	1663	1400	6203
	f. Other Expenses	<b>6988</b>	7169	5462	24678
	Total Expenses	<b>29545</b>	44170	24440	121209
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	<b>17406</b>	26973	11729	63284
4	Other Income	<b>4066</b>	437	1309	6576
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	<b>21472</b>	27410	13038	69860
6	Finance Costs	<b>41</b>	273	45	374
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	<b>21431</b>	27137	12993	69486
8	Exceptional items	<b>0</b>	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	<b>21431</b>	27137	12993	69486
10	Tax Expense:	<b>4693</b>	5659	2734	14889
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	<b>16738</b>	21478	10259	54597
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	<b>16738</b>	21478	10259	54597
14	Share of profit / (loss) of associates	<b>0</b>	0	0	0

15	Minority Interest	0	0	0	0
16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	16738	21478	10259	54597
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2653	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				214825
19	Earnings per Share:				
a)	Basic Earnings Per Share before extra-ordinary items Rs.	12.61	16.19	7.74	41.15
	Diluted Earnings Per Share before extra-ordinary items Rs.	12.61	16.19	7.73	41.15
b)	Basic Earnings Per Share after extra-ordinary items Rs.	12.61	16.19	7.74	41.15
	Diluted Earnings Per Share after extra-ordinary items Rs.	12.61	16.19	7.73	41.15

A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding - No. of shares - Percentage of shareholding	63512190 47.85%	63512190 47.85%	63427130 47.82%	63512190 47.85%
2	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	Nil  69222100 100%	Nil  69222100 100%	Nil  69222900 100%	Nil  69222100 100%
		52.15%	52.15%	52.18%	52.15%

	Particulars	Quarter ended 30 <sup>th</sup> June 2012
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	5
	Disposed off during the quarter	5
	Remaining unresolved at the end of the quarter	Nil

**NOTES:**

1. The above results for the quarter ended 30<sup>th</sup> June 2012, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 4<sup>th</sup> August, 2012 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.

4. Figures for the previous year/period have been regrouped or recasted, wherever necessary, as per format revised by SEBI in conformity with the amended Schedule VI to the Companies Act, 1956. Figures of quarter ended 31<sup>st</sup> March, 2012 are the balancing figures between audited figures in respect of the financial year ended 31<sup>st</sup> March, 2012 and the published year-to-date figures upto the third quarter of that financial year.

for Divi's Laboratories Limited

Place: Hyderabad  
Date: 4<sup>th</sup> August, 2012

Dr. Murali K. Divi  
Chairman & Managing Director